Biphenyl

Biphenyl

SCHEMBL4601210

CC(C)(C)[SiH2]Cl.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
CYP1A2 P05177 2/20 0.43
SLC22A2 O15244 1/20 0.40
SLC22A1 O15245 1/20 0.40
SLC22A3 O75751 1/20 0.40
SLC6A4 P31645 1/20 0.40
KIF11 P52732 1/20 0.39
TAAR1 Q96RJ0 3/20 0.38
MAPK1 P28482 2/20 0.38
CYP3A4 P08684 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NOTUM Q6P988 1/20 0.38
MMP3 P08254 1/20 0.38
BCL2L1 Q07817 1/20 0.38
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
AKT1 P31749 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL2598157 0.82 ALDH1A1 (0.75) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL4466468 0.79 ALDH1A1 (0.60) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL5459788 0.79 ALDH1A1 (0.60) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL27550995 0.78 ALDH1A1 (0.69) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL27335451 0.78 ALDH1A1 (0.69) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL27709311 0.78 ALDH1A1 (0.69) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL27745920 0.78 ALDH1A1 (0.69) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL383979 0.78 ALDH1A1 (0.69) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL22288245 0.77 ALDH1A1 (0.56) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3
Biphenyl SCHEMBL1193167 0.74 ALDH1A1 (0.53) ALDH1A1CYP1A2SLC22A2SLC22A1SLC22A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100535054-C Silica film forming material, silica film and preparation method thereof FUJITSU LTD (JP) 2009-09-02 CN disclosed
EP-1727814-B1 NUCLEOSIDE ANALOGUES WITH ANTIVIRAL ACTIVITY UNIV CATANIA (IT) 2008-04-30 EP disclosed
CN-1891757-A Silica film forming material, silica film and method of manufacturing the same FUJITSU LTD (JP) 2007-01-10 CN disclosed
EP-1727814-A1 NUCLEOSIDE ANALOGUES WITH ANTIVIRAL ACTIVITY Universita' Degli Studi Di Catania (IT) 2006-12-06 EP disclosed
EP-1546164-A4 (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF LG LIFE SCIENCES LTD (KR) 2006-06-07 EP disclosed
US-20060111324-A1 (+)-Ttrans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl)methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof LG LIFE SCIENCES (KR) 2006-05-25 US disclosed
WO-2005082896-A1 NUCLEOSIDE ANALOGUES WITH ANTIVIRAL ACTIVITY UNIVERSITA' DEGLI STUDI DI CATANIA (IT) 2005-09-09 WO disclosed
EP-1546164-A1 (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF LG Life Sciences Ltd. (KR) 2005-06-29 EP disclosed
WO-2004029064-A1 (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF LG LIFE SCIENCES LTD. (KR) 2004-04-08 WO disclosed
US-5401649-A Conjugated with luminescent label, immunogenic carrier, ligand, enzyme, or hapten, detection of cyclosporins SYNTEX (U.S.A.) INC. (US) 1995-03-28 US disclosed
US-5300634-A Process for producing maltooligosaccharide derivative WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1994-04-05 US disclosed
EP-0512808-A1 Process for producing maltooligosaccharide derivative WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1992-11-11 EP disclosed
US-5089390-A Determination of cyclosporins with luninescent labeled conjugate; immunoassay SYNTEX (U.S.A.) INC. (US) 1992-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111324-A1 (+)-Ttrans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl)methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof TTR, HAVCR2, PNP ALDH1A1 1984/4885CYP1A2 1326/4885SLC22A2 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.